低剂量持续静脉滴注吉西他滨一线治疗晚期非小细胞肺癌的临床研究.pdfVIP

Chinese Journal of Cancer, 2创6， 25(8) :995-998 995 低剂最持续静脉滴注宙西他滇…钱治疗 晚期非小细胞肺癌的临床研究 • ，)各床研究· 熊建萍，张凌，钟陆行，邱峰，郭宇玲，廉虹舌， 罗辉 Phase 11 Trial of Prolonged Inf阳us创ion of Low翩-dose Gemcitab剧ine in Advanced Non唰Small Ce刨11 Lung Cancer Treatment XIONG Jian.币伊. GUO Yu-Ling , LlAN Hong.…Yun , LUO Hui 南昌大学第一附属医院 肿瘤科， 江西南昌 33ω06 Dep翩翩nt Qf Oncology , 1页e First Affilioted Hospital , Nanchang University , Nanchang , Jiangxi , 33ω06 ， 只 R. China 通讯作者:熊建萍 Correspondence to: XIONG Jian-Ping Tel ,86…791-8692559 Fax ,86-791-8693861 E-mail :jpxiong@ 基金项目:江西省卫生厅基金 (No.2oo2翩。6) Grant, Foundation from Health Bureau of Jiangxi Province (No. 2∞2-06) 收稿日期 :2005唰 11-05 修因日期 :2∞6-04-13 [ABSTRACT] 臼ACKGROUND OBJECTIV应: Gemcitabine combined with cisplatin has been taken as the front-line regimen for patients with advanced non-small-cell lung cancer (NSCLC) ‘ The routine use of gemcitabine is íntravenous injectíon of a dose of 1 000 mg/m 2 within 30 minutes on days 1 and 8 , and the treatment is repeated every 3 weeks. This study was to evaluate the efficacy and safety of 6-hour continuous infusion of low dose of gemcítabine plus císplatin for patíents wíth advanced NSCLC. MEγHODS: Forty-eíght patients wíth measurable stage 111 日/IV NSCLC and without chemotherapy were enrolled. AII of them received 6-hour continuous ínfusion of gemcitabíne 250 mg/m 2 on day 1 and 8 plus císplatin 75 mg/m 2 on day 2- 4 for more than 2 cycles. The cycle was repeated every 3 weeks. RESULTS: AII 48 patients were evaluated for toxicity and 46 for response 圄 The overall response r创e was 32.5% (completed and pa同ial response rates were 2.2% and 30.3% , respectively). The median tíme to progressíon was 5.1 months , median survival time was 10.2 months; and 1 幽year survival rate was 36.6%. The maín hematologic toxicity consisted of 60.4% neutropenia , 39.5% thrombocytopenia. Grade 111 - IV neutropenía and thrombocytopenia were 20.8% and 12.5%, respectively. CONCLUSION: Six-hour prolonged infu